Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Home iloprost infusion for Raynaud's disease with ischemic ulcers in systemic sclerosis
2016-002984-32Phase 4Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iloprost in systemic sclerosis (SSc) and Raynaud disease, sponsored by Policlinico Gemelli. Primary endpoint: Raynaud's disease intensity. Started Feb 2018; status: terminated.
02
Drugs
iloprost
03
Conditions
systemic sclerosis (SSc)Raynaud disease
Beyond the preview
Go deeper on 2016-002984-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002984-32.